AI智能总结
To inform the potential development of a national formulary In Scope�����������������������������������������������������������������������������������������������������������������������������������������������������������4Out of Scope����������������������������������������������������������������������������������������������������������������������������������������������������5 Background�����������������������������������������������������������������������������������������������������������������5 Approach to Developing the List������������������������������������������������������������������������������6 Generating the Initial List of Products for Panel Review����������������������������������������������������������������������������������7Addressing Gaps in the Context of Canada�����������������������������������������������������������������������������������������������������9Application of the Criteria for Inclusion and Exclusion of Products����������������������������������������������������������������12 About the Consultation An Act Respecting Pharmacare(Pharmacare Act)1became law in October2024�It proposes a foundationfor a national universal pharmacare program in Canada�ThePharmacare Actoutlines principles that theMinister of Health is to consider when working toward the implementation of national universal pharmacare�Among the activities listed under thePharmacare Act, it specifies that Canada’s Drug Agency (CDA-AMC)would undertake the following actions, at the request of the Minister of Health, including providing advice ona range of topics related to prescription drugs and related products; preparing a list of essential prescriptiondrugs and related products to inform the potential development of a national formulary; developing optionsfor a national bulk purchasing strategy for federal, provincial, and territorial governments; and a report on theprogress made to advance a pan-Canadian strategy to promote the appropriate use of prescription drugsand related products�1 The purpose of this consultation is to engage interested parties on the proposed list of essentialprescription drugs and related products to inform the potential development of a national formulary� This discussion paper sets out the approach to developing the proposed essential prescription drugs andrelated products list and the products that may be included to inform the potential development of a nationalformulary. This consultation aims to provide an opportunity to hear from interested parties and understandthe different perspectives on this subject matter. The comments will be shared with the advisory panel andwill be used to inform the advisory panel’s final report. There are3 questions embedded in this discussion paperthat ask interested parties to consider thefollowing: 1�Do you have suggestions that could enhance the process for including and excluding products?2�Do you have specific suggestions to support the process for updating the proposed list over time?3�The proposed list includes drugs and related products that are used frequently and listed on mostpublic drug plans. Can you identify potential additional commonly prescribed drug(s) in Canada thathave not already been assessed by the advisory panel proposed inAppendix 2(e�g�, high usagein Canada and listed on most public drug plans)? If yes, provide specific drug example(s) andsupporting information to be considered�Important note: specific drug(s) recommended to be included on the proposed list must meet theprocess and criteria outlined in this discussion paper. Supporting information may include a healthtechnology assessment (HTA) recommendation from a recognized body in Canada; where there is noHTA recommendation available, specific reference to a clinical guidance document that is generallyaccepted by experts in Canada may be included along with the number of public drug plans listingstatus, among other relevant information� Public Posting of Commentaries To encourage conversation on this topic and ensure transparency, CDA-AMC will publish the comments wereceive through this engagement�By participating in the engagement sessions on this topic, you, orthe organization you represent, agree to the full disclosure of the information, including a summaryanalysis of the themes�CDA-AMC reserves the right to refuse to post feedback, in whole or in part, that,in our sole discretion, is deemed to be unrelated to the issue under engagement; contains complaints and/or compliments about identifiable individuals; contains personal identifiers and/or other information thatmay identify a third party; is abusive, obscene, harassing, threatening, or otherwise inappropriate; includesdefamatory or libellous comments; and/or does not comply with the CDA-AMCTerms of Useand/orPrivacy Policy� Setting the Context A time-limited advisory panel was formed to prepare the product list and to identify the methodology thatmay be used to inform the potential development